medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2022, Number 1

<< Back Next >>

Rev Nefrol Dial Traspl 2022; 42 (1)

Glomerulonephritis due to minimal change disease post COVID-19 vaccine AstraZeneca

Arias C, Pérez PF, Caliva E, Farías B, Iotti A, Rubio D

Language: Spanish
References: 20
Page: 65-68
PDF size: 420.89 Kb.


ABSTRACT

We report a case of a 28-year-old woman with minimal change disease secondary nephrotic syndrome 48 hours after the administration of the AstraZeneca SARS-CoV2 vaccine. The patient had suffered idiopathic nephrotic syndrome in childhood treated empirically with corticosteroids and cyclosporine, in complete remission from the age of 9. Some reports suggest that glomerular disease might appear infrequently associated to some vaccines.


REFERENCES

  1. Clajus C, Spiegel J, Bröcker V, Chatzikyrkou C,Kielstein JT. Minimal change nephrotic syndrome inan 82 year old patient following a tetanus-diphteriapoliomyelitis-vaccination. BMC Nephrol. 2009;10:21.doi: 10.1186/1471-2369-10-21.

  2. Kielstein JT, Termühlen L, Sohn J, Kliem V. Minimalchange nephrotic syndrome in a 65-year-old patientfollowing influenza vaccination. Clin Nephrol.2000;54(3):246-8.

  3. Kikuchi Y, Imakiire T, Hyodo T, Higashi K, Henmi N,Suzuki S, et al. Minimal change nephrotic syndrome,lymphadenopathy and hyperimmunoglobulinemiaafter immunization with a pneumococcal vaccine. ClinNephrol. 2002;58(1):68-72. doi: 10.5414/cnp58068.

  4. Abeyagunawardena AS, Goldblatt D, Andrews N,Trompeter RS. Risk of relapse after meningococcalC conjugate vaccine in nephrotic syndrome. Lancet.2003;362(9382):449-50. doi: 10.1016/s0140-6736(03)14072-x.

  5. Lebedev L, Sapojnikov M, Wechsler A, Varadi-LeviR, Zamir D, Tobar A, et al. Minimal change diseasefollowing the Pfizer-BioNTech COVID-19 vaccine.Am J Kidney Dis. 2021;78(1):142-5. doi: 10.1053/j.ajkd.2021.03.010.

  6. D’Agati VD, Kudose S, Bomback AS, Adamidis A,Tartini A. Minimal change disease and acute kidneyinjury following the Pfizer-BioNTech COVID-19vaccine. Kidney Int. 2021;100(2):461-3. doi: 10.1016/j.kint.2021.04.035.

  7. Morlidge C, El-Kateb S, Jeevaratnam P, ThompsonB. Relapse of minimal change disease followingthe AstraZeneca COVID-19 vaccine. Kidney Int.2021;100(2):459. doi: 10.1016/j.kint.2021.06.005.

  8. Leclerc S, Royal V, Lamarche C, Laurin LP. Minimalchange disease with severe acute kidney injuryfollowing the Oxford-AstraZeneca COVID-19 vaccine:a case report. Am J Kidney Dis. 2021;78(4):607-10. doi:10.1053/j.ajkd.2021.06.008.

  9. Cara-Fuentes GM, Johnson RJ, Garin EH. Cytokines asactive factors in minimal change nephrotic syndrome.En: Kaneko K., ed. Molecular mechanisms in thepathogenesis of idiopathic nephrotic syndrome. Springer,Tokyo: 2016, p. 105-40. https://doi.org/10.1007/978-4-431-55270-3_8.

  10. Shalhoub RJ. Pathogenesis of lipoid nephrosis: adisorder of T-cell function. Lancet. 1974;2(7880):556-60. doi: 10.1016/s0140-6736(74)91880-7.

  11. Vivarelli M, Massella L, Ruggiero B, Emma F. Minimalchange disease. Clin J Am Soc Nephrol. 2017;12(2):332-45. doi: 10.2215/CJN.05000516.

  12. Gillion V, Jadoul M, Demoulin N, Aydin S, DevresseA. Granulomatous vasculitis after the AstraZeneca anti-SARS-CoV-2 vaccine. Kidney Int. 2021;100(3):706-7.doi: 10.1016/j.kint.2021.06.033.

  13. Anderegg MA, Liu M, Saganas C, Montani M,Vogt B, Huynh-Do U, et al. De novo vasculitis aftermRNA-1273 (Moderna) vaccination. Kidney Int.2021;100(2):474-6. doi: 10.1016/j.kint.2021.05.016.

  14. Sacker A, Kung V, Andeen N. Anti-GBM nephritiswith mesangial IgA deposits after SARS-CoV-2 mRNAvaccination. Kidney Int. 2021;100(2):471-2. doi:10.1016/j.kint.2021.06.006.

  15. Rahim SEG, Lin JT, Wang JC. A case of gross hematuriaand IgA nephropathy flare-up following SARS-CoV-2vaccination. Kidney Int. 2021;100(1):238. doi:10.1016/j.kint.2021.04.024.

  16. Aydın MF, Yıldız A, Oruç A, Sezen M, Dilek K,Güllülü M, et al. Relapse of primary membranousnephropathy after inactivated SARS-CoV-2 virusvaccination. Kidney Int. 2021;100(2):464-5. doi:10.1016/j.kint.2021.05.001.

  17. Ciuntu A. The role of cell signaling molecules inthe pathogenesis of glomerulonephritis in children.Moldovan Med J. 2021;64(2):37-4. doi: 10.52418/moldovan-med-j.64-2.21.07.

  18. Kudose S, Batal I, Santoriello D, Xu K, Barasch J,Peleg Y, et al. Kidney Biopsy Findings in Patients withCOVID-19. J Am Soc Nephrol. 2020;31(9):1959-68.doi: 10.1681/ASN.2020060802.

  19. Ishimoto T, Shimada M, Gabriela G, Kosugi T,Sato W, Lee PY, et al. Toll-like receptor 3 ligand,polyIC, induces proteinuria and glomerular CD80,and increases urinary CD80 in mice. Nephrol DialTransplant. 2013;28(6):1439-46. doi: 10.1093/ndt/gfs543.

  20. Xing CY, Saleem MA, Coward RJ, Ni L, WitherdenIR, Mathieson PW. Direct effects of dexamethasone onhuman podocytes. Kidney Int. 2006;70(6):1038-45.doi: 10.1038/sj.ki.5001655.




2020     |     www.medigraphic.com